Carabella for bulging discs explained: what it is, what clinical research shows, who may be a candidate, and realistic expectations from an Istanbul regenerative medicine clinic.
Carabella is a mesenchymal stem cell (MSC)-based investigational product that has been studied as a potential biological approach to intervertebral disc degeneration — the underlying process driving most bulging, herniated, and degenerating discs. It is not a drug in the conventional sense, and it is not currently approved as a standard treatment in most countries. But it represents a specific, documented application of cell-based therapy to spinal disc pathology, and that distinction matters for any patient trying to make sense of what 'stem cells for back pain' actually means.
Each intervertebral disc has two main components: a tough outer ring called the annulus fibrosus, and a gel-like inner core called the nucleus pulposus. This nucleus is mostly water and proteoglycans — large molecules that hold moisture and give the disc its shock-absorbing quality. As the disc ages, is loaded, or is injured, the nucleus loses water content. It shrinks. The annulus weakens. The disc can then bulge outward, pressing on nearby nerve roots or the spinal cord itself.
Mesenchymal stem cells do not simply replace lost nucleus cells. The mechanism is more nuanced — and, honestly, more interesting. MSCs work primarily through paracrine signalling: the chemical messages they release to their immediate environment. In a degenerating disc, transplanted or homed MSCs have been shown in preclinical models to secrete growth factors including TGF-β1, GDF-5, and IGF-1, which may support nucleus pulposus cell survival, slow matrix degradation, and modulate the local inflammatory milieu.
Carabella — developed as an allogeneic MSC product specifically for disc degeneration — has progressed through early-phase clinical investigation. A Phase 1/2 trial reported in the early 2020s evaluated intradiscal injection of MSCs in patients with chronic discogenic low back pain. Results suggested that the procedure was well-tolerated, with no serious adverse events directly attributed to the cell product, and that a proportion of patients reported clinically meaningful reductions in pain scores and improvements in disability indices at 12-month follow-up.
Several important questions remain open — and a responsible clinic should name them, not sidestep them.
Not every patient with back pain is suitable for intradiscal MSC therapy. Candidacy requires careful clinical assessment, and the criteria matter both for safety and for the likelihood of meaningful benefit.
Our medical team does not offer MSC therapy as a standalone product dispensed on request. Every patient who enquires about disc-related regenerative treatment goes through a structured clinical review before any recommendation is made.
We use umbilical cord-derived MSCs from ethically donated, fully consented sources. The cells are processed in GMP-aligned conditions and cryopreserved at −196°C. Every batch undergoes identity verification via surface marker expression (CD73+/CD90+/CD105+ confirmed; CD45−/CD34− to exclude haematopoietic contamination) and sterility testing covering HIV, HBV, HCV, CMV, EBV, mycoplasma, and endotoxins.
Patients who respond to intradiscal MSC therapy typically describe a gradual change — not an overnight shift. The most commonly reported improvements are: reduction in baseline pain intensity (often measured on a 0–10 numerical rating scale), improvement in walking distance or tolerance for sitting, and reduction in reliance on analgesics or anti-inflammatory medications. Some patients show MRI evidence of disc signal improvement or slowed height loss at 6–12 months.
No medical procedure is risk-free. Intradiscal injection carries a small but real risk of discitis (disc infection), nerve injury from the needle, or bleeding at the injection site. In published MSC disc trials, serious adverse events directly attributable to the cell product itself have been rare — but the total number of patients studied remains relatively small, which limits the ability to detect uncommon complications.
This is one of the most common questions we receive — and it deserves a direct answer, not a vague reassurance.
There are situations where regenerative medicine is not the right first step — and a responsible clinic names these clearly. If you have significant motor weakness in a limb, worsening foot drop, loss of bowel or bladder control, or signs of cauda equina syndrome, you need urgent surgical evaluation. These are not situations for a 6-month biological trial.
Carabella is not currently approved as standard of care in most countries, including the US, UK, EU member states, or Australia. It has progressed through Phase 1 and Phase 2 clinical trials, with early data suggesting safety and possible clinical benefit in carefully selected patients. Patients accessing it abroad — including in Turkey — do so within the legal medical framework of the destination country, not as an approved product in their home jurisdiction. This distinction is important and should be understood before travelling for treatment.
Intradiscal injection is the primary route studied for disc regeneration. A thin needle is guided into the nucleus pulposus using real-time fluoroscopic or CT imaging — the same image guidance used for standard epidural or discography procedures. The MSC suspension is then deposited precisely within the disc space. In some protocols, intravenous MSC infusion is used as a systemic adjunct to modulate broader inflammation. The choice of route depends on disc morphology, number of affected levels, and the treating physician's clinical judgement.
Most published protocols for disc degeneration involve one to two intradiscal injections per disc level, sometimes with a systemic IV component. Unlike some regenerative applications where repeat dosing is more common, the intradiscal environment is relatively contained — repeated needle entry carries cumulative procedural risk. Our medical team will review your imaging and symptom history to recommend the most appropriate protocol for your specific situation.
Not reliably — and a clinic that tells you otherwise is not being honest. Surgical decompression remains the standard of care for disc herniations with significant neurological compromise: motor weakness, progressive nerve damage, cauda equina involvement. For patients without these urgent features, MSC therapy may be a reasonable option to explore before committing to surgery — but it cannot be guaranteed to prevent surgery, and for some patients it will not provide sufficient relief. The decision should be made jointly with your spine specialist and your regenerative medicine physician, with full information on both sides.
MSC therapy overall has been studied in clinical trials for over 15 years, across conditions including graft-versus-host disease, multiple sclerosis, Crohn's disease, and cardiovascular disease — a research base that informs the broader safety profile. For intradiscal MSC injection specifically, follow-up data published through 24 months are reassuring in terms of serious adverse events, with no signals of tumour formation, immune rejection, or disc space collapse attributable to the cell product. Beyond 24 months, systematic data for disc applications are still accumulating. This is not the same as saying it is unsafe — it means the evidence base is still maturing.
Ask about cell source (allogeneic vs. autologous, and why), donor screening panel, GMP processing documentation, injection technique and who performs it, adverse event rates from the clinic's own patient cohort, what follow-up looks like after you return home, and what happens if you do not respond. A clinic that answers these questions clearly — including the uncomfortable ones — is a clinic worth trusting. One that deflects them is not.
If you have been living with chronic disc-related pain, have tried conservative management, and are exploring biological options before surgery — Carabella-type MSC therapy may be worth a serious clinical conversation. Not because it is guaranteed to work, but because the underlying science is credible, the early safety data are reassuring, and the treatment fills a genuine gap in the current standard-of-care pathway for patients who are not yet surgical candidates or who want to avoid surgery if possible.
Carabella for Bulging Discs: What the Evidence Actually Shows in 2026